

LA JOLLA PHARMACEUTICAL CO

Form 8-K

April 10, 2003

**Table of Contents**

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 or 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): April 10, 2003

**La Jolla Pharmaceutical Company**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

---

(State or Other Jurisdiction of Incorporation)

---

(Commission File Number)

---

(IRS Employer Identification No.)

6455 Nancy Ridge Drive, San Diego, California

92121

---

(Address of Principal Executive Offices)

---

(Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

N/A

---

(Former Name or Former Address, if Changed Since Last Report)

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

**SIGNATURES**

**EXHIBIT INDEX**

**EXHIBIT 99.1**

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On April 10, 2003, the Company issued a press release announcing the closure of its open-label safety study of Riquent™. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL COMPANY**

Date: April 10, 2003

By:           /s/ Steven B. Engle

\_\_\_\_\_  
Steven B. Engle  
Chairman and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release